首页 Sarepta疗法(usSRPT)-基本信息

Sarepta疗法(usSRPT)-基本信息

日报更新时间:04-20 10:53

周报更新时间:04-18 04:06

行情信息

今开价:70.56

最高价:72.48

成交量:270122.0

昨收价:71.3

最低价:70.236

最新价:72.34

行情图标
概要信息

中文名称:Sarepta疗法


英文名称:Sarepta Therapeutics


简介:Sarepta Therapeutics, Inc.是一家全资附属的生物制药公司,致力于发现和开发独特的基于RNA的稀有治疗感染疾病


电话:1-617-2744000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Sarepta Therapeutics, Inc.于1980年以AntiVirals之名注册成立,在上市前不久,公司将其名称从AntiVirals更名为AVI BioPharma,股票代码为AVII,并于2012年7月分别从AVI BioPharma更名为Sarepta Therapeutics,股票代码变更为:SRPT。截至2018年,该公司有一种批准的药物。 公司主要产品是Morpholino低聚物(吗啉代寡聚体,PMOs),合成核酸类似物,由James Summerton构思,由Summerton与Dwight Weller共同发明,最初以NeuGene Antisense的名称开发。由于吗啉代寡聚体可与RNA形成序列特异性双链复合物,因此它们适用于反义治疗。在一种应用中,翻译阻断,吗啉代寡聚体与已知致病基因产生的信使RNA结合,以防止其翻译成蛋白质。Morpholinos还可以作为剪接转换寡核苷酸,靶向前mRNA以改变剪接,从而引起成熟mRNA结构的变化(批准的药物eteplirsen的机制)。Morpholinos已被测试用于广泛的应用,包括预防血管成形术后的心脏再狭窄,冠状动脉旁路移植物的治疗,多囊肾病的治疗,药物代谢的重定向,治疗导致Duchenne肌营养不良症(DMD)的一些突变和抑制传染病。到目前为止,公司最大的临床和商业成功是治疗DMD。 Sarepta Therapeutics公司提供EXONDYS 51(Eteplirsen,商用阶段产品),一种用于治疗杜氏肌营养不良症(DMD)的疾病改善疗法,这是一种由缺乏肌营养不良蛋白引起的罕见遗传性肌肉萎缩疾病。 公司还提供Golodirsen,一种与肌营养不良蛋白pre-mRNA的外显子53结合的候选产物,其导致在具有基因突变的患者的mRNA加工期间排除或跳过外显子,所述基因突变适于外显子53跳跃。 Casimersen,使用磷酰二胺吗啉代寡聚物(PMO)化学和外显子跳跃技术来跳过DMD基因的外显子45。 SRP-5051,一种肽缀合的PMO,其与肌营养不良蛋白前mRNA的外显子51结合,导致在具有适合外显子51跳跃的基因突变的患者的mRNA加工期间排除外显子。萨雷普塔治疗公司与Nationwide Children's Hospital建立了战略联盟,根据研究和许可选项协议推进微肌营养不良蛋白基因治疗计划,以及根据许可协议进行的Galgt2基因治疗计划;和Genethon合作研究和独家许可选项协议下推进微肌营养不良蛋白基因治疗计划。Sarepta Therapeutics公司还与杜克大学签订了研究和许可选项协议,以促进肌肉营养不良的基因编辑CRISPR / Cas9技术;与Summit (Oxford) Ltd.达成合作和许可协议,将Summit的utrophin调制器产品中的产品商业化。萨雷普塔治疗公司通过美国的专业分销商和专业药店网络以及国际分销商分销其产品。

交易日期 交易人 职位 类型 交易份额 价格
2019-05-23 O Neill (Gilmore Neil) Officer Sell 4630 119.31
2019-05-22 Wigzell (Hans Lennart Rudolf) Director Sell 10000 120.00
2019-05-22 Wigzell (Hans Lennart Rudolf) Director Buy 10000 7.80
2019-05-22 O Neill (Gilmore Neil) Officer Buy 12000 --
2019-03-27 Mahatme (Sandesh) Chairman of the Board Sell 2953 118.68
2019-03-27 Mahatme (Sandesh) Chairman of the Board Buy 6649 --
2019-03-27 Howton (David Tyronne) General Counsel Sell 2362 118.68
2019-03-27 Howton (David Tyronne) General Counsel Buy 5319 --
2019-03-27 Cumbo (Alexander) Officer Sell 2165 118.68
2019-03-27 Cumbo (Alexander) Officer Buy 4876 --
2019-03-18 Mahatme (Sandesh) Chief Financial Officer Buy 3511 13.90
2019-03-18 Mahatme (Sandesh) Chief Financial Officer Buy 11768 23.85
2019-03-18 Mahatme (Sandesh) Chief Financial Officer Buy 164 13.71
2019-03-18 Mahatme (Sandesh) Chief Financial Officer Buy 43 13.71
2019-03-18 Mahatme (Sandesh) Chief Financial Officer Sell 2625 126.47
2019-03-03 Nicaise (Claude M.D.) Director Buy 1633 --
2019-03-03 Behrens (M Kathleen) Director Buy 1633 --
2019-03-03 Gray (Mary Ann) Director Buy 1633 --
2019-03-03 Bonney (Michael W) Director Buy 1633 --
2019-03-03 Wigzell (Hans Lennart Rudolf) Director Buy 1633 --
2019-02-27 Mahatme (Sandesh) Chairman of the Board Sell 4781 --
2019-02-27 Howton (David Tyronne) General Counsel Sell 3825 --
2019-02-27 Cumbo (Alexander) Officer Sell 3375 --
2019-02-06 Mahatme (Sandesh) Chief Financial Officer Sell 65000 145.00
2019-02-06 Mahatme (Sandesh) Chief Financial Officer Buy 65000 23.85

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
TimesSquare Capital Management, LLC 1095935 1.48% 233345 27.05% 2019-03-31
BlackRock Fund Advisors 3606740 4.85% 8133 0.23% 2019-07-31
Sands Capital Management, LLC 3617094 4.88% 522327 16.88% 2019-03-31
Fidelity Management & Research Company 4006517 5.39% -875942 -17.94% 2019-07-31
Fidelity SelectCo, LLC 4095741 5.51% -765000 -15.74% 2019-07-31
BlackRock Inc 4187264 5.65% -657967 -13.58% 2019-03-31
Vanguard Group Inc 5999672 8.09% 134349 2.29% 2019-03-31
Fidelity Management and Research Company 9205294 12.41% 331837 3.74% 2019-03-31
FMR Inc 10956596 14.78% 391419 3.70% 2019-03-31
T. Rowe Price Associates, Inc. 3543067 4.78% -843109 -19.22% 2019-03-31
HHG PLC 2666043 3.60% 826449 44.93% 2019-03-31
Janus Capital Management LLC 2640228 3.55% 128867 5.13% 2019-07-31
Columbia Mgmt Investment Advisers, LLC 1108627 1.50% 870106 364.79% 2019-03-31
Ameriprise Financial Inc 1150200 1.55% 873817 316.16% 2019-03-31
venBio Select Advisor LLC 1195000 1.61% -80000 -6.27% 2019-03-31
Fidelity International Ltd 1229971 1.66% -338895 -21.60% 2019-03-31
State Street Corporation 1353466 1.83% 106102 8.51% 2019-03-31
Adage Capital Partners Gp LLC 1650000 2.23% -700144 -29.79% 2019-03-31
Fidelity Institutional Asset Management 1751302 2.36% 59582 3.52% 2019-03-31
Vanguard Investments Australia Ltd 1943096 2.61% 63639 3.39% 2019-07-31
Fred Alger Management Inc 1083053 1.46% -602585 -35.75% 2019-03-31
Geode Capital Management, LLC 1317506 1.78% 726354 122.87% 2018-12-31
Deutsche Asset Management Investment GmbH 2669479 3.60% 2010542 305.12% 2019-05-31
Waddell & Reed Financial Inc 1184145 1.60% 240510 25.49% 2018-12-31
Waddell & Reed Investment Management Co 1184145 1.66% 240510 25.49% 2018-12-31
Amvescap Plc. 1135342 1.70% 178760 18.69% 2018-09-30
Eagle Asset Management, Inc. 1067318 1.60% 379162 55.10% 2018-09-30
Jennison Associates LLC 1219503 1.82% 5604 0.46% 2018-09-30
Gilder Gagnon Howe & CO LLC 979595 1.47% -6279 -0.64% 2018-09-30
BlackRock Institutional Trust Company NA 1652971 2.47% -6078 -0.37% 2018-06-30
RTW INVESTMENTS, LLC 978551 1.46% 290280 42.18% 2018-06-30
Susquehanna International Group, LLP 937082 1.40% 630493 205.65% 2018-06-30
Millennium Management LLC 858407 1.29% 507588 144.69% 2018-06-30
Invesco Advisers, Inc 860480 1.30% 308405 55.86% 2018-06-30
Susquehanna Financial Group, LLLP 927334 1.40% 633493 215.59% 2018-06-30
State Street Corp 1467473 2.21% -761515 -34.16% 2018-06-30
Capital Ventures International 3576970 5.53% 3576970 -- 2017-12-11
Goldman, Sachs & Co. 677135 1.02% 168858 33.22% 2018-06-30
Deutsche Asset Mgmt Invst Gesenschaft 632240 0.95% -15290 -2.36% 2018-06-30
Deutsche Asset & Wealth Management Investment GmbH 636105 0.97% 20819 3.38% 2018-08-29
Lord, Abbett & Co LLC 536233 0.81% 138381 34.78% 2018-06-30
Renaissance Technologies Corp 495478 0.75% 239700 93.71% 2018-06-30
Alyeska Investment Group, L.P. 453224 0.68% 272943 151.40% 2018-06-30
Northern Trust Investments N A 713759 1.09% -413 -0.06% 2018-03-31
Tourbillon Capital Partners LP 758413 1.16% -168812 -18.21% 2018-03-31
Ivy Investment Management Co 698100 1.05% 698100 -- 2018-06-30
Prudential Investments LLC 892365 1.36% -- -- 2018-05-31
Heights Capital Management Inc 981232 1.51% 981232 -- 2017-12-31
Elk Creek Partners LLC 703424 1.09% -13092 -1.83% 2017-12-31
Emerald Mutual Fund Advisers Trust 701228 1.08% -15544 -2.17% 2017-12-31
Morgan Stanley & Co Inc 698971 1.08% 536485 330.17% 2017-12-31
Healthcor Management LP 1309960 2.02% 107190 8.91% 2017-12-31
Emerald Advisers Inc 886979 1.37% -6505 -0.73% 2017-12-31
BlackRock Advisors LLC 841278 1.29% -13525 -1.58% 2018-02-28
Point72 Asset Management, L.P. 1645275 2.55% -380131 -18.77% 2017-09-30
Camber Capital Management LLC 1400000 2.17% 100000 7.69% 2017-09-30
Citadel Advisors Llc 2035190 3.15% 1032421 102.96% 2017-09-30
Perceptive Advisors LLC 1089961 1.97% -681068 -38.46% 2017-06-30
Jefferies & Company Inc 2316214 4.26% 1630585 237.82% 2016-09-30
Redmile Group, LLC 640400 1.18% 640400 -- 2016-09-30
EverPoint Asset Management, LLC 600000 1.10% 600000 -- 2016-09-30
Hudson Bay Capital Management LP 539619 0.99% 84619 18.60% 2016-09-30
Sabby Management LLC 536282 0.99% -247215 -31.55% 2016-09-30
The Vanguard Group 2290714 4.00% 32596860 0.10% 1999-11-30
Richard J. Barry 3165014 4.00% 45038149 0.10% 1999-11-30
BlackRock, Inc. 3202261 4.00% 45568174 0.10% 1999-11-30
Columbia Wanger Asset Management, LLC 3272400 4.00% 46566252 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 500000 0.67% -30000 -5.66% 2019-06-30
Vanguard Total Stock Market Index Fund 1927012 2.59% 62425 3.35% 2019-06-30
Vanguard Small Cap Index 1797476 2.42% 35678 2.03% 2019-06-30
T. Rowe Price Health Sciences Fund 1220493 1.64% -80700 -6.20% 2019-06-30
T. Rowe Price New Horizons Fund 1075737 1.45% -79300 -6.87% 2019-06-30
Vanguard Small Cap Growth Index Fund 1032249 1.39% 33817 3.39% 2019-06-30
Vanguard Extended Market Index Fund 957590 1.29% -8155 -0.84% 2019-06-30
Ivy Science and Technology Fund 766600 1.03% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 732015 0.98% 7495 1.03% 2019-07-30
Fidelity Canadian Growth Company Fund 698731 0.94% 77995 12.56% 2019-03-31
Eventide Gilead Fund 505000 0.68% -- -- 2019-03-31
Janus Henderson Triton Fund 508396 0.68% -- -- 2019-06-30
Janus Henderson Enterprise Fund 618883 0.83% 71150 12.99% 2019-06-30
Janus Mid Cap Growth Tr 618883 0.83% 71150 12.99% 2019-06-30
First Trust NYSE Arca Biotech Fund 638151 0.86% -1538 -0.24% 2019-07-31
Fidelity Advisor 690000 0.93% -210000 -23.33% 2019-06-30
PGIM Jennison Health Sciences Fund 690340 0.93% -- -- 2019-06-30
Fidelity Canadian Growth Company Class 698731 0.94% 77995 12.56% 2019-03-31
DWS Biotech 528000 0.71% 395943 299.83% 2019-04-30
DWS Verm 1600000 2.16% 1200000 300.00% 2019-04-30
Vanguard Small Cap Index Fund 1763173 2.38% 11050 0.63% 2019-04-30
SPDR 512906 0.69% -- -- 2019-04-30
Carillon Eagle Small Cap Growth Fund 522334 0.73% -- -- 2018-12-31
AZ InvestEd Ivy Science & Tech Fund 766600 1.08% 68500 9.81% 2018-12-31
BlackRock Health Sciences Opps Port 527025 0.74% -87330 -14.21% 2019-01-31
iShares Russell 2000 Growth ETF 469502 0.66% 810 0.17% 2018-06-21
Delaware Smid Cap Growth Fund 447425 0.67% -22425 -4.77% 2018-12-31
Oppenheimer Global Opportunities Fund 500000 0.75% -- -- 2018-04-30
Vanguard Total Stock Mkt Idx 1561928 2.35% 1582 0.10% 2018-07-31
Delaware Smid Cap Growth A 374375 0.56% 24625 7.04% 2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq 366700 0.55% 109000 42.30% 2018-06-30
Alger Spectra A 406023 0.61% -33864 -7.70% 2018-06-30
Eagle Small Cap Growth A 522334 0.79% -173570 -24.94% 2018-06-30
T. Rowe Price Health Sciences 1611512 2.43% 303312 23.19% 2018-06-30
T. Rowe Price New Horizons 1431964 2.16% 300300 26.54% 2018-06-30
iShares Nasdaq Biotechnology 743798 1.22% -1416 -0.19% 2018-09-12
Vanguard Small Cap Growth Index Inv 894284 1.35% 13279 1.51% 2018-07-31
Prudential Jennison Health Sciences A 821050 1.24% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 816752 1.23% 900 0.11% 2018-07-31
AZ InvestEd Ivy Science & Tech E 698100 1.05% 698100 -- 2018-06-30
BlackRock Health Sciences Opps Inv A 704155 1.06% -- -- 2018-07-31
iShares Russell 1000 Growth 203193 0.32% -- -- 2018-07-18
FIAM Small Company Pool 353900 0.54% 113800 47.40% 2018-03-31
Oppenheimer Global Opportunities A 500000 0.76% -- -- 2018-04-30
iShares Russell 2000 Growth 469502 1.14% 810 0.17% 2018-06-21
Columbia Mid Cap Growth Z 310433 0.48% -- -- 2018-03-31
Lord Abbett Developing Growth A 382258 0.59% -8182 -2.10% 2018-01-31
Emerald Growth A 358157 0.55% -49336 -12.11% 2018-01-31
Alger Capital Appreciation Instl I 280107 0.43% 65790 30.70% 2017-11-30
Fidelity Spartan 266434 0.41% -- -- 2017-12-31
Invesco Global Health Care A 234526 0.36% -- -- 2017-09-30
AST Small-Cap Growth 213931 0.33% 3850 1.83% 2017-11-30
CREF Stock R1 173600 0.32% -2354 -1.34% 2016-12-31
TIAA-CREF Small-Cap Equity Instl 128200 0.23% -- -- 2016-12-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 121588 0.22% 23026 23.36% 2016-12-31
Tekla Healthcare Investors 46150 0.08% 46150 -- 2016-09-30
Columbia Acorn USA Fund 241227 0.60% 3533 1.50% 2015-09-30
Highland Long/Short Healthcare Fund 326564 0.80% 104317 46.90% 2015-06-30
Fidelity Advisor® Biotechnology Fund 371104 0.90% -- -- 2015-09-30
SPDR® S&P Biotech ETF 660826 1.60% 4308 0.70% 2015-11-19
iShares Russell 2000 (AU) 712022 1.80% -447 -0.10% 2015-11-18
Columbia Acorn Fund 1465091 3.50% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 1705108 4.10% -- -- 2015-09-30

Mary Ann Gray Founder of Gray Strategic Advisors LLC, Mary Ann Gray is President at this company. She is also on the board of Sarepta Therapeutics, Inc. She previously was Senior Scientist at Poniard Pharmaceuticals, Inc., Advisor at Burrill & Co. LLC, Senior Scientist at Schering-Plough Corp., Fund Manager at Federated Investment Management Co., Principal at Kidder Peabody, Portfolio Manager at Federated Kaufmann Fund, Principal at Warburg Dillon Read LLC and Principal at Raymond James & Associates, Inc. She received an undergraduate degree from the University of South Carolina and a doctorate from the University of Vermont.
Douglas S. Ingram Mr. Douglas S. Ingram is a President, Chief Executive Officer & Director at Sarepta Therapeutics, Inc. and a Chairman at RemitPro, Inc. He is on the Board of Directors at Relay Therapeutics, Inc., Sarepta Therapeutics, Inc. and Allergan Foundation. Mr. Ingram was previously employed as a Chief Executive Officer & Director by Chase Pharmaceuticals Corp., a Vice Chairman by Nemus Bioscience, Inc., a President by Allergan, Inc., an Attorney by Gibson, Dunn & Crutcher LLP, and a Trustee by Suburban Hospital Healthcare System (Maryland). He also served on the board at Endo International Plc, Pacific Mutual Holding Co., ECC Capital Corp., Pacific Life Insurance Co. and Volcom, Inc. He received his undergraduate degree from Arizona State University and a graduate degree from the University of Arizona.
David Tyronne Howton David Tyronne Howton holds the position of Secretary, Senior Vice President & General Counsel at Sarepta Therapeutics, Inc. Mr. Howton previously held the position of Secretary, Chief Legal Officer & Senior VP at Vertex Pharmaceuticals, Inc. and Chief Healthcare Compliance Officer at Genentech, Inc. He received an undergraduate degree from Yale University and a graduate degree from Northwestern University School of Law.
M. Kathleen Behrens Wilsey Founder of Kew, Inc., M. Kathleen Behrens Wilsey presently holds the position of Chairman of MiMedx Group, Inc. and Chairman of Sarepta Therapeutics, Inc. She is also on the board of IGM Biosciences, Inc. Dr. Wilsey previously occupied the position of Chairman & President for National Venture Capital Association, President & Chief Executive Officer at Kew, Inc., Director-Science, Technology & Economic Policy at The National Research Council, Managing Director & General Partner at Robertson Stephens & Co. and Managing Director at RS Investment Management Co. LLC. M. Kathleen Behrens Wilsey received an undergraduate degree and a doctorate from the University of California, Davis.
Richard Jon Barry Richard Jon Barry founded Eastbourne Capital Management LLC. Mr. Barry is on the board of Sarepta Therapeutics, Inc., Elcelyx Therapeutics, Inc. and MiMedx Group, Inc. and Partner at San Diego Padres Baseball Club and Managing Member at Gsm Fund LLC. Mr. Barry previously occupied the position of Partner at Eastbourne Capital Management LLC, Analyst at Regal Asset Management Corp. and Portfolio Manager at RS Investment Management Co. LLC. Mr. Barry received an undergraduate degree from The Pennsylvania State University.
Michael W. Bonney Michael W. Bonney is a businessperson who has been the head of 5 different companies. He is Chairman of Magenta Therapeutics, Inc., Chairman for Alnylam Pharmaceuticals, Inc. and Executive Chairman of Kaleido Biosciences, Inc. Mr. Bonney is also Chairman-Trustees Board at Bates College and on the board of 5 other companies. Michael W. Bonney previously held the position of Director-National Business at Zeneca Pharmaceuticals, Partner at Third Rock Ventures LLC, Vice President-Sales & Marketing at Biogen, Inc., Director at Cubist Pharmaceuticals LLC and Director at Biotechnology Innovation Organization. Mr. Bonney received an undergraduate degree from Bates College.
Hans Lennart Rudolf Wigzell Dr. Hans Lennart Rudolf Wigzell, MD PhD, is a Member-Supervisory Board at Valneva SE, Independent Director at Sarepta Therapeutics, Inc., Independent Director at Karolinska Development AB, Independent Director at Swedish Orphan Biovitrum AB, Independent Director at RaySearch Laboratories AB, Founder at Affibody Medical AB, a Member at Royal Swedish Academy of Sciences, a Member at Royal Swedish Academy of Engineering Sciences, a Member at American Academy of Arts & Sciences, a Member at Finnish Society of Sciences & Letters, a Member at European Molecular Biology Organization, Chairman at Stockholm School of Entrepreneurship, a Member at Royal Danish Academy of Sciences & Letters, and Chairman at Rhenman & Partners Asset Management AB. He is on the Board of Directors at Valneva SE, Sarepta Therapeutics, Inc., Karolinska Development AB, Swedish Orphan Biovitrum AB, RaySearch Laboratories AB, Humabs LLC, Wigzellproduktion AB, Cadila Pharmaceuticals Sweden AB, and NeoDynamics AB. Dr. Wigzell was previously employed as a Member-Supervisory Board by Probi AB, President by Karolinska Institutet, Chairman by ExThera AB, General Director by Smittskyddsinstitutet, a Member-Supervisory Board by Epixis SA, and a Member-Supervisory Board by Biovitrum AB. He also served on the board at Intercell AG and Mertiva AB. He received his doctorate degree from Karolinska Institutet.
Gunnar J. Hanson Gunnar J. Hanson is Senior Director-Research Chemistry at Sarepta Therapeutics, Inc. In his past career he was Vice President for Joyant Pharmaceuticals, Inc. and Principal at Pfizer Inc. and Principal at Serenex, Inc. (a subsidiary of Pfizer Inc.). Dr. Hanson received an undergraduate degree from the University of Oregon and a doctorate from Massachusetts Institute of Technology.
Joan Nickerson Currently, Joan Nickerson is Vice President-Human Resources of Sarepta Therapeutics, Inc. Ms. Nickerson previously occupied the position of Head-Sales, Product & Service Information at Aushon BioSystems, Inc. and Head-Human Resources at Dyax Corp. She received an undergraduate degree from the University of Massachusetts and an MBA from Simmons College (Massachusetts).
Hans Lennart Rudolf Wigzell Dr. Hans Lennart Rudolf Wigzell, MD PhD, is a Member-Supervisory Board at Valneva SE, Independent Director at Sarepta Therapeutics, Inc., Independent Director at Karolinska Development AB, Independent Director at Swedish Orphan Biovitrum AB, Independent Director at RaySearch Laboratories AB, Founder at Affibody Medical AB, a Member at Royal Swedish Academy of Sciences, a Member at Royal Swedish Academy of Engineering Sciences, a Member at American Academy of Arts & Sciences, a Member at Finnish Society of Sciences & Letters, a Member at European Molecular Biology Organization, Chairman at Stockholm School of Entrepreneurship, a Member at Royal Danish Academy of Sciences & Letters, and Chairman at Rhenman & Partners Asset Management AB. He is on the Board of Directors at Valneva SE, Sarepta Therapeutics, Inc., Karolinska Development AB, Swedish Orphan Biovitrum AB, RaySearch Laboratories AB, Humabs LLC, Wigzellproduktion AB, Cadila Pharmaceuticals Sweden AB, and NeoDynamics AB. Dr. Wigzell was previously employed as a Member-Supervisory Board by Probi AB, President by Karolinska Institutet, Chairman by ExThera AB, General Director by Smittskyddsinstitutet, a Member-Supervisory Board by Epixis SA, and a Member-Supervisory Board by Biovitrum AB. He also served on the board at Intercell AG and Mertiva AB. He received his doctorate degree from Karolinska Institutet.
Claude Nicaise Currently, Claude Nicaise is Head-Strategic Orphan Regulatory Affairs at Ovid Therapeutics, Inc. Dr. Nicaise is also on the board of Sarepta Therapeutics, Inc. and Minoryx Therapeutics SL and Member of American Society of Clinical Oncology, Member of American Society of Hematology, Member of American Society for Microbiology, Member of European Society for Medical Oncology and Owner at Clinical Regulatory Services LLC. He previously was Vice President-Global Development at Bristol-Myers Squibb Co., VP-Clinical Development & Regulatory Affairs at Formula Pharmaceuticals, Inc., Senior Vice President-Global Regulatory Affairs at Alexion Pharmaceuticals, Inc. and Deputy Medical Officer at Outlook Therapeutics, Inc. Dr. Nicaise received a doctorate from Universit�0�1�0�8 Libre de Bruxelles.
Ian Estepan Presently, Ian Estepan occupies the position of Chief Of Staff & Vice President at Sarepta Therapeutics, Inc. Mr. Estepan previously held the position of Director-Strategic Planning at EHI Patent Co. LLC and Portfolio Manager at Spectra Investment Group LLC. Mr. Estepan received an undergraduate degree from Columbia University.
Sandesh Mahatme Presently, Sandesh Mahatme occupies the position of Chief Financial & Business Officer, Executive VP at Sarepta Therapeutics, Inc. He is also on the board of Flexion Therapeutics, Inc., Elcelyx Therapeutics, Inc. and Aeglea Biotherapeutics, Inc. and Member of New York State Bar Association. In his past career Mr. Mahatme held the position of Senior VP-Finance & Corporate Development at Celgene Corp. Sandesh Mahatme received a graduate degree from New York University School of Law and a graduate degree from Cornell Law School.
David Tyronne Howton David Tyronne Howton holds the position of Secretary, Senior Vice President & General Counsel at Sarepta Therapeutics, Inc. Mr. Howton previously held the position of Secretary, Chief Legal Officer & Senior VP at Vertex Pharmaceuticals, Inc. and Chief Healthcare Compliance Officer at Genentech, Inc. He received an undergraduate degree from Yale University and a graduate degree from Northwestern University School of Law.
David Tyronne Howton David Tyronne Howton holds the position of Secretary, Senior Vice President & General Counsel at Sarepta Therapeutics, Inc. Mr. Howton previously held the position of Secretary, Chief Legal Officer & Senior VP at Vertex Pharmaceuticals, Inc. and Chief Healthcare Compliance Officer at Genentech, Inc. He received an undergraduate degree from Yale University and a graduate degree from Northwestern University School of Law.
Diane Berry Presently, Diane Berry occupies the position of VP-Global Health Policy & Government Affairs at Sarepta Therapeutics, Inc. She received an undergraduate degree from Northwestern University and a graduate degree from Tufts University.
Diane Berry Presently, Diane Berry occupies the position of VP-Global Health Policy & Government Affairs at Sarepta Therapeutics, Inc. She received an undergraduate degree from Northwestern University and a graduate degree from Tufts University.
Alexander Gery Cumbo Alexander Gery Cumbo is on the board of Ra Pharmaceuticals, Inc. and Chief Commercial Officer & Executive VP of Sarepta Therapeutics, Inc. In his past career Mr. Cumbo held the position of Vice President-Sales & Treatment Education at Vertex Pharmaceuticals, Inc. Mr. Cumbo received an undergraduate degree from Auburn University.
Alexander Gery Cumbo Alexander Gery Cumbo is on the board of Ra Pharmaceuticals, Inc. and Chief Commercial Officer & Executive VP of Sarepta Therapeutics, Inc. In his past career Mr. Cumbo held the position of Vice President-Sales & Treatment Education at Vertex Pharmaceuticals, Inc. Mr. Cumbo received an undergraduate degree from Auburn University.
Guriqbal S. Basi Presently, Guriqbal S. Basi occupies the position of Chief Scientific Officer of Sarepta Therapeutics, Inc. In the past he held the position of Senior Vice President-Research at Adverum Biotechnologies, Inc., Chief Scientific Officer at Circuit Therapeutics, Inc., Chief Scientific Officer of Symic Bio, Inc. and Chief Science & Technology Officer at Elan Pharmaceuticals, Inc. Guriqbal S. Basi received a doctorate from the University of Illinois and an undergraduate degree from The Ohio State University.
Gilmore O'Neill Presently, Gilmore O'Neill holds the position of Chief Medical Officer & Senior Vice President for Sarepta Therapeutics, Inc. He is also on the board of Massachusetts Biotechnology Council and Member of American Academy of Neurology. In the past he was Senior Vice President at Biogen, Inc. Dr. O'Neill received an undergraduate degree from University College Dublin and a graduate degree from Harvard University.
Marco A. Passini Marco A. Passini is Senior Director-Biology at Sarepta Therapeutics, Inc.
Louise Rodino-Klapac Louise Rodino-Klapac is Senior Vice President-Gene Therapy at Sarepta Therapeutics, Inc.
Gary Charbonneau Currently, Gary Charbonneau occupies the position of Senior Vice President-Global Regulatory Affairs at Sarepta Therapeutics, Inc. Mr. Charbonneau previously was Vice President-Regulatory Affairs of Allergan, Inc. He received an undergraduate degree from California Polytechnic State University (San Luis Obispo) and a graduate degree from the University of Southern California.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐